bluebird bio, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration
Depreciation and amortization
Stock-based compensation expense
Noncash research and development expense (finance lease)
Noncash operating lease expense
Loss on fixed assets disposal
Unrealized loss (gain) on equity securities
Excess inventory reserve
Non-cash interest expense
Other non-cash items
Gain on foreign currency exchange rates
Proceeds from sale of accounts receivable
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Transfer of invoices to Factor
Inventory
Operating lease right-of-use assets
Accounts payable
Operating lease liabilities
Deferred revenue
Collaboration research advancement
Accrued expenses and other liabilities
Accrued interest payable under finance lease

Net cash used in operating activities
Cash flows from investing activities:
Purchase of property, plant and equipment
Proceeds from previously transferred invoices
Purchases of marketable securities
Proceeds from maturities of marketable securities
Proceeds from sales of marketable securities
Proceeds from sale of Durham, North Carolina manufacturing facility
Purchase of intangible assets
Proceeds from sale of priority review voucher
Net cash provided by investing activities
Cash flows from financing activities:
Reimbursement of assets under financing lease obligation
Payments on financing lease obligation
Net cash transferred to 2seventy bio at separation
Proceeds from the issuance of debt, net of fees paid to lender
Proceeds allocated to detachable warrants issued in conjunction with debt
Payments of debt issuance costs
Proceeds from public offering of common stock, net of issuance costs
Public Offering
Regeneron Collaborative Arrangement
Private Placement
Total proceeds from public offering of common stock, net of issuance costs

Proceeds from exercise of stock options and ESPP contributions
Proceeds from the transfer of invoices
Principal payments on finance leases
Other financing activities
Net cash provided by financing activities

Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental cash flow disclosures:
Reduction of right of use asset and associated lease liability due to lease reassessment
Issuance of unrestricted stock awards to settle accrued employee compensation
Cash paid during the period for interest
Cash paid during the period for income taxes
Right-of-use assets obtained in exchange for operating lease liabilities
Purchases of property, plant and equipment included in accounts payable and accrued expenses
Purchases of intangible assets included in accrued expenses
Right-of-use assets obtained in exchange for finance lease liabilities
Offering expenses included in accounts payable and accrued expenses
Beneficiary interest obtained in transferred invoices
Cash paid (refunded) during the period for income taxes

Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash included in receivables and other current assets
Restricted cash included in restricted cash and other non-current assets

Comments